Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
CellaVision AB ( (SE:CEVI) ) just unveiled an update.
CellaVision AB announced the departure of its CFO, Magnus Blixt, who will leave the company on July 18, 2025, after twelve years of service. His contributions have been significant in the company’s growth and success, and the search for his replacement will begin immediately. This change in management comes as CellaVision continues to expand its product portfolio and market presence, maintaining its focus on delivering profitable growth.
More about CellaVision AB
CellaVision is a global medical technology company based in Lund, Sweden, specializing in the development and sale of systems for routine analysis of blood and other body fluids. These systems are crucial for diagnosing diseases, especially infections and cancer. The company leverages expertise in sample preparation, image analysis, artificial intelligence, and automated microscopy to enhance laboratory workflows. CellaVision operates through global partners and local market support organizations in over 40 countries, with a growth target of 15% annually.
Average Trading Volume: 27,225
Current Market Cap: SEK4.65B
Find detailed analytics on CEVI stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue